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DiscoveryThe lack of novel antimicrobial drugs under development coupled with the increasing occurrence of
resistance to existing antibiotics by community and hospital acquired infections is of grave concern.
The targeting of biosynthesis of the peptidoglycan component of the bacterial cell wall has proven to
be clinically valuable but relatively little therapeutic development has been directed towards the
transglycosylase step of this process. Advances towards the isolation of new antimicrobials that target
transglycosylase activity will rely on the development of the enzymological tools required to identify
and characterise novel inhibitors of these enzymes. Therefore, in this article, we review the assay meth-
ods developed for transglycosylases and review recent novel chemical inhibitors discovered in relation to
both the lipidic substrates and natural product inhibitors of the transglycosylase step.
 2014 Published by Elsevier Inc. This is an open access article under the CC BY license (http://creative-
commons.org/licenses/by/3.0/).1. Introduction
In the search for new treatments of bacterial infections and to
combat the increasing threat of resistance to existing antimicrobi-
als, there is renewed interest in the exploitation of existing
validated targets with novel approaches. With respect to bacterial
cell wall biosynthesis, the validity of the peptidoglycan biosyn-
thetic apparatus is well established, particularly in consideration
of the fact that many of these antimicrobial targets exist at or
beyond the extra-cytoplasmic surface of the cell membrane and
are well conserved across all bacterial species [1,2]. The
biosynthetic pathway leading to peptidoglycan precursor lipid II
and the generalised scheme for its polymerisation into the
peptidoglycan layer is well documented. Brieﬂy, uridine 50-pyro-
phosphoryl-N-acetyl muramyl-L-alanyl-c-D-glutamyl-meso-diami-
nopimelyl-D-alanyl-D-alanine (UDP-MurNAc-L-Ala-D-Glu-L-(Lys/
meso-DAP)-D-Ala-D-Ala) or its L-lysine derivative (UDP-MurNAc-
L-Ala-D-Glu-L-(Lys)-D-Ala-D-Ala) is produced in the cytoplasmic
pathway before linkage at the cytoplasmic membrane surface to
an undecaprenyl (C55) carrier lipid, prior to the addition of GlcNAc,
forming lipid II [3]. This peptidoglycan precursor is then trans-
ferred to the outer surface of the cytoplasmic membrane whereit is polymerised by monofunctional transglycosylases and class
A bifunctional Penicillin Binding Proteins (PBPs) into long glycan
chains [4] (Fig. 1). The transpeptidase activity of Class A and B PBPs
then produce inter-strand peptide cross-links from pentapeptides
emanating from adjacent glycan chains. The resulting polymer
has the mechanical strength and rigidity required to resist cyto-
plasmic osmotic stress and forms a scaffold for a number of extra-
cellular structures and functions.
Both academic and industrial effort over many decades has
been directed towards the transpeptidase function of the penicil-
lin binding proteins (PBPs) in this context, with the development
of many generations of b-lactam-based antibiotics [5]. However,
there has been relatively little development directed towards
the essential transglycosylase function required to provide the
polymeric transpeptidase substrate, which can also be the product
of the same bifunctional peptidoglycan biosynthetic enzyme [6].
Dual inhibition of both transglycosylase and transpeptidase
functions would be a powerful antimicrobial strategy providing
therapeutic options in a variety of scenarios, including those cur-
rently untreatable. Since the active site of the transglycosylase
enzymes exist at the membrane surface where peptidoglycan
intermediates are presented to the enzymes, this has been viewed
as a difﬁcult interface to target [7]. In addition, consideration of
the catalytic function of the enzymes leads to the conclusion that
the transglycosylase enzymes have long extended active sites,
which traditionally have been viewed as more difﬁcult to target
[8]. Nevertheless, nature has already provided an exemplar
solution to this issue in the form of the moenomycin group of
antimicrobials, which appear to mimic the polymerised form of
Fig. 1. Schematic diagram of the transglycoylase active site showing doner and acceptor sites. Residue numbers in the acceptor sites refer to those determined for S. aureus
monofunctional transglycosylase in relation to lipid II analogue as described by Huang et al. [28].
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macokinetics prohibits the use of moenomycins in humans, yet
this group of antibiotics has been used for decades in agriculture,
principally in animal husbandry applications [9]. Remarkably,
there is almost no incidence of resistance to these compounds,
which implies that the transglycosylase activity may have signif-
icant attraction for future targeting.
Understanding the active site architecture of the transglyco-
sylase through X-ray crystallographic analysis along with
advances in biochemical study through the provision of native
substrate and chemically deﬁned probes, and the development
of assay technologies that can support industry standard screen-
ing techniques, provide a new prospect for inhibitor discovery for
new generation chemotherapy (Fig. 1). In this review article we
provide a perspective of the assay technologies available and
compounds recently discovered, that are pertinent in that
context.2. Assays for transglycosylase activity
Bacterial transglycosylases have been studied for over 50 years
[10]. The discovery and development of novel transglycosylase
inhibitors has been highly dependent on appropriate activity
assays. However, progress has been hampered by the lack of
quantitative and high throughput approaches capable of fast,
accurate enzyme activity measurement. In addition, such efforts
have been affected by the relative chemical complexity and lack
of availability of the transglycosylase substrate, lipid II. Chemical
and chemi-enzymatic approaches to overcome this hurdle have
been reported by several groups, [11–22]. In addition, lipid II
and other peptidoglycan intermediates have become available
from the UK Bacterial Cell Wall Biosynthesis Network (UK-BaC-
WAN). Since both the transglycosylase enzymes and substrate
are within a lipid membrane environment, assay conditions and
design needs to factor in these chemical properties and physical
limitations. The solution of several X-ray crystal structures of
mono-functional and bifunctional enzymes has enhanced struc-
ture based drug design efforts [7,23–28], an advance which has
depended upon the design and implementation of reliable and
accurate high-throughput assays. The following sections discuss
the main assay types currently available, whilst Fig. 2 and Table 1
provide concise summaries.2.1. Paper and thin layer chromatography
Paper chromatography was ﬁrst used to study the full polymer-
isation of peptidoglycan using particulate enzyme preparations
isolated from Staphylococcus aureus with radiolabelled UDP-
N-acetylmuramyl-pentapeptide and UDP-N-acetylglucosamine as
substrates [29]. The assay was adapted to use [14C]-labelled lipid
II with membrane protein preparations [22]. The use of penicillin
to inhibit transpeptidase and carboxypeptidase activities of bifunc-
tional PBPs facilitated analysis of the transglycosylation reaction,
and the assay has been used for several studies [30–34]. Whilst
scintillation counting allows collection of quantitative data in a
stopped assay format, paper chromatography remains a cumber-
some technique that is low throughput and lacks the ability to rap-
idly characterise the product post reaction.
Thin layer chromatography has also been used to study poly-
merisation, using ﬂuorescent lipid II for detection [35]. With the
ﬂuorescent substrate, a dansyl reporting group was linked to the
e-amino group of the lysine side chain of the pentapeptide via a sul-
fonamide linkage to generate ﬂuorescent dansyl lipid II. Transglyco-
sylase kinetic parameters have been shown to be unaffected by the
presence of this group (see Section 2.6 for further discussion).
The presence of a dansyl group prevents transpeptidation from
occurring on this molecule, which results in a transglycosylation-
speciﬁc assay when used as the sole substrate in a stopped assay
format. Paper and thin layer chromatography are both highly sen-
sitive techniques, allowing very small amounts of material to be
detected. However, the assay remained inherently low throughput
and qualitative.2.2. Polyacrylamide gel based techniques
Transglycosylase activity can also be studied using a polyacryl-
amide gel based assay developed from a technique initially used in
the late 1980s. Tricine–SDS–PAGE [36,37] is a variation on the
more commonly used glycine SDS-PAGE that has been optimised
for low molecular weight proteins. Glycan products made of
repeating disaccharide units have a net negative charge, allowing
their separation by electrophoresis, and shorter chain lengths in
particular are within the optimum separation size range. The sys-
tem was modiﬁed to separate the polymeric products of isolated
transglycosylase domains using [14C]-lipid II and lipid IV as
Fig. 2. Schematic of the main techniques currently available to assay transglycosylase activity allowing inhibitor discovery as discussed in Section 2. A cartoon representation
of a typical reaction trace is shown for each technique and section numbers corresponding to the text are included.
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full-length PBPs were used along with penicillin G to inhibit trans-
peptidase activity. These assays were able to detect the presence of
polymeric products, and also allowed visualisation of a range of
glycan chain lengths for the ﬁrst time. Fluorescently labelled lipid
II, as discussed above, can also be used as a substrate in gel-based
assays [39].
The main strength of this technique is the unique ability to visu-
alise discrete lengths of polymerised material. However this is only
possible for shorter chain lengths, with longer polymerised mate-
rial forming an unresolved smear or high molecular weight prod-
uct, which does not enter the resolving gel phase [38,39], thus
the techniques is not particularly sensitive. The main limitation
with this approach is the lack of quantitative data in a continuous
assay format. Unpolymerised and polymerised products can be
quantiﬁed using densitometry for both ﬂuorescent and radioactive
material, and rates can be crudely estimated using time-course
experiments. Nonetheless, gel-based assays are useful for studying
the processivity of enzymes, and they allow simple comparison
between different enzymes, which other systems cannot do at
present. It has been reported that separation of glycan chains using
this approach is not affected by other proteins, salts or additives in
reaction buffers [38].2.3. High-pressure liquid chromatography
High-pressure liquid chromatography (HPLC) has been used to
separate native muropeptides extracted from bacteria [40] and
adapted to identify the products of in vitro transglycosylase activity
using suitably labelled ﬂuorescent lipid II intermediates created
either pre or post reaction [18,41] In the method described by
Schwartz et al. 2001, reactions were in the presence of Penicillin
G and products are labelled post reaction with ﬂuorescamine
via the e-amino of lysine in the lipid II pentapeptide side chain
before being separated by anion exchange [18]. Size exclusion
chromatography has been used to separate mixtures of unlabelledand Alexa 647-ﬂuor labelled lipid II substrates and polymerised
products [26]. In these cases the reaction products were applied
directly to the column with no requirement for sample prepara-
tion, although N-acetylmuramidase digestion could also be used
prior to separation [28]. When the lipid II substrate is radiola-
belled, this technique can be adapted to monitor both transglyco-
sylase and transpeptidase products of the reaction by appropriate
post reaction enzymatic treatment of the resulting polymer
[42,43] since the e-group of lysine or DAP at position 3 of the pen-
tapeptide stem is free to participate in transpeptidation. HPLC
assays in this context are reasonably sensitive, allowing low levels
of material to be detected, although sensitivity is dependent on the
exact equipment being used and its capabilities.2.4. Fluorometric continuous assays
The ﬁrst continuous, coupled assay of transglycosylase activity
reported was based upon the increased quantum yield of ﬂuores-
cence signal from a dansyl ﬂuorophore when in a hydrophobic
micellar environment [41]. Under the assay conditions used, dan-
syl lipid II (see Section 2.1) is presented to the transglycosylase
in detergent micelles, and can be polymerised into glycan chains.
Whilst N-acetylmuramidase digestion of the glycan chains
generates aqueous soluble labelled monomers, resulting in a
reduction in ﬂuorescence as the environment of the ﬂuorophore
changes from hydrophobic micellar environment to the soluble
phase. The initial rate of this decreased ﬂuorescence was attributed
to incorporation of lipid II into glycan chains and was used to
determine kinetic parameters for Escherichia coli PBP1b transglyco-
sylase activity [41]. The presence of the dansyl group in the third
position of the lipid II pentapeptide, prevented subsequent trans-
peptidation by bifunctional enzymes, allowing measurement of
transglycosylation alone. This assay [41] has been converted to a
multi-well format, which enables the rapid parallel screening of
a range of reaction conditions [44]. This can allow, therefore, the
screening and determination of optimal conditions for multiple
Table 1
Summary of transglycosylase activity assays as discussed in the text.
Assay type Section number Stopped or continuous Sensitivity Inhibitor screens
Paper/thin layer chromatography 2.1 Stopped High No
Polyacrylamide gel 2.2 Stopped Low No
HPLC 2.3 Stopped Medium No
Fluorometric: continuous ﬂuorescence 2.4 Continuous High Yes
Fluorometric: FRET 2.4 Continuous High Yes
Moenomycin displacement 2.5 Continuous High Yes
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study of these membrane proteins. In addition, this demonstrated
the basis for utility of this assay in library screening of compounds
to identify potential novel inhibitors, as did a second study [45].
Whilst measuring changes in ﬂuorescence serve well for
efﬁcient enzyme and inhibitor characterisation, they are not
always suitable for high throughput, pharmaceutical industry stan-
dard, compound screening. Thus, the development of time resolved
Förster Resonance Energy Transfer (FRET) assays is of interest to
address these requirements since it is possible to avoid contami-
nating ﬂuorescence signals from compounds within the libraries
screened. Huang et al. utilised a FRET-Based Lipid II Analogue
(FBLA), with a Coumarin ﬂuorophore in the third position of the
peptide stem and a dimethylamino-azobenzenesulfonyl quencher
in the lipid chain of the same substrate molecule [46]. Prior to
polymerisation of the FBLA, the coumarin ﬂuorescence is
quenched, but once polymerised into glycan chains, the quencher
is lost as the polyprenyl lipid tail is released from the transglyco-
sylase-substrate complex, and the polymerised glycan product is
ﬂuorescent. Inclusion of N-acetylmuramidase to digest the glycan
product into smaller and more soluble intermediates enhanced
the ﬂuorescence changes observed. When adapted to a 1536-well
format, a very high throughput approach was achieved, and a
library of 120,000 compounds was screened. A number of
previously characterised inhibitors including moenomycin were
identiﬁed in screens utilising a variety of Class A PBPs (including
Acinetobacter baumannii PBP1b, Clostridium difﬁcile PBP, E. coli
PBP1b, Klebsiella pneumoniae PBP1b, and Mycobacterium tuberculo-
sis PonA1). This was the ﬁrst application of FRET in the study of
transglycosylation, and represents a new sensitive method for con-
tinuously following transglycosylation activity.
The high throughput nature of these assays is a clear advantage,
and the ability to continuously monitor enzyme activity and accu-
rately determine kinetic parameters for a wide range of conditions
and enzymes makes this a powerful approach. Both types of ﬂuo-
rometric assay described here measure overall transglycosylation
rates, and are capable of identifying inhibitors which interfere with
substrate availability as well as those that directly inhibit enzyme
activity, which may increase the range of possible lead compounds
identiﬁed. However, both assays use a modiﬁed lipid II substrate
that differs from the native substrate by addition of large ﬂuores-
cent groups, and this will be discussed further in Section 2.6.
2.5. High throughput screening based on moenomycin displacement
A different approach to high throughput assay design has been
taken by a number of groups, based upon chemically modiﬁed
derivatives of moenomycin, which binds to the transglycosylase
active site with high afﬁnity.
Following a surface plasmon resonance (SPR) study of various
immobilised Class A PBPs binding to moenomycin, Cheng et al.
designed a highly sensitive ﬂuorescence anisotropy based assay
utilising a ﬂuorescein labelled moenomycin (F-Moe) [47]. When
bound to the transglycosylase active site F-Moe displayed
ﬂuorescence anisotropy properties which decreased when theF-Moe was displaced by compounds binding competitively to the
active site at comparable or greater afﬁnity. Of all class A PBP
homologs tested, it was found that a combination of Helicobacter
pylori PBP1a with F-Moe had a Kd of 25 (±14) nM and anisotropy
reaching 0.2 upon binding of the ligand. This high throughput
assay was used to screen 57,000 compounds with a Z0 value of
0.895, which proved valuable as a robust initial screen and identi-
ﬁed a number of moenomycin derivatives and small molecules,
with 3 small molecule hits showing both antibacterial and trans-
glycosylase inhibitory action (HTS6-8) (Table 2). The major limita-
tion of this approach is the inability of compounds with relatively
low afﬁnity to displace high afﬁnity moenomycin, precluding for
example fragment based drug design or delineation of structure
activity relationships of transglycosylase inhibitors.
Gampe et al. described a ﬂuorescence polarisation, displace-
ment assay based upon the binding of a ﬂuorescently labelled,
truncated analogue of moenomycin that displayed weaker binding
than moenomycin A [48]. This ﬂuorescent probe represented a
minimal pharmacophore to speciﬁcally identify low micromolar
inhibitor binding to the transglycosylase active site and was
designed from a consideration of the X-ray crystal structures of
moenomycin in complex with transglycosylase active sites. This
probe was used in 1536-well plate format using non-essential
S. aureus monofunctional transglycosylase enzyme SgtB [49],
against 110,000 compounds in the Harvard Medical School screen,
resulting in a Z0 value of 0.78 and initially identifying 186 hits [48].
After dose response studies and the elimination of ﬂuorescent
compounds from the initial hits, a number of leads were identiﬁed
including one (Compound 10) with inhibition constants ranging
from 2.6 mM to 95 nM against transglycosylase enzymes from
S. aureus, Enterococcus faecalis, and E. coli (Table 2).
Both the assays described by Cheng et al. [47] and Gampe et al.
[48] utilise the properties of existing drug-enzyme interaction for
the basis of detection, eliminating the need for lipid II substrates
in the primary screen and the detection of the reaction products.
Both are also sensitive methods, which can detect low levels of dis-
placement. However these assays rely on chemical modiﬁcation of
the pharmacophore for detection in a ﬂuorescence mode and the
ability of library compounds to displace existing interactions
between enzyme and that pharmacophore.
2.6. Prospects for assay development in transglycosylase inhibitor
discovery
The transglycosylase activity of puriﬁed, recombinant PBPs is
highly sensitive to the conditions in vitro. In particular: tempera-
ture, DMSO, detergents and divalent cations can have signiﬁcant
effects [41,44,50,51]. Also, despite recent advances in membrane
protein biochemistry, the level of understanding of the separate
functions of Class A PBPs and MGTs and more importantly, their
coordinated activity with other cell wall biosynthetic proteins as
well as cell division is still somewhat lacking. Additionally, studies
have shown that the transmembrane portion of the PBPs may be
highly involved in substrate binding as well as in transglycosylase
activity [27,28,39]. In fact, enzyme activities of full-length enzymes
Table 2
Reference and chemical structure of transglycosylase inhibitors discussed.
Reference Compound name/features Year
Soﬁa et al.
[68]
1999
TS30153 TS30663
TS30888
He et al.
[72]
2000
AC326-a
Halliday
et al.
[6]
2006
ACL 19273
Cheng
et al.
[47]
2008
HTS-6 HTS-7 HTS-8
Gampe
et al.
[48]
2013
Compound 10
Garneau
et al.
[76]
2004
Compound 5
Cheng
et al.
[80]
2010
Compound 24
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Table 2 (continued)
Reference Compound name/features Year
Huang
et al.
[28]
2012
Analogue 3
Huang
et al.
[28]
2012
Compound 31
Dumbre
et al.
[78]
2012
Compound 21 Compound 62
Huang
et al.
[46]
2013
Compound 19 Compound 20
Compound 24 Compound 25
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hypothesis. Assaying full-length enzymes in a membrane environ-
ment and in the presence of a full complement of cell wall proteins
may be a highly signiﬁcant factor in future inhibitor discovery, and
this is undoubtedly highly challenging.
It has been demonstrated that transglycosylase kinetic parame-
ters are largely unaffected by addition of side groups on the third
position lysine or DAP of the lipid II pentapeptide [16,41]. The
effects of ﬂuorophores on the lipid and peptide chains were com-
pared, and those on the lipid chain appear less likely to interfere
with enzyme-substrate recognition [52]. Even taking this into con-
sideration, the kinetic parameters measured still appear too low to
meet the demands of growing and dividing cells. In order to sup-
port growth, an E. coli cell would require 300 transglycosylase reac-
tions/minute/molecule, but published data on E. coli PBP1a (as a
representative example) in vitro gave only 0.8 transglycosylase
reactions/minute/molecule [53]. Thus, there is a signiﬁcant gap
between observed in vitro behaviour and that required to support
life in vivo, leading to the hypothesis that other regulatory and
coordinating factors are necessary for a more accurate reﬂection
of transglycosylase activity during in vitro analysis [54].Taking all of the above into account, it may be desirable to mea-
sure alternative product release, rather than polymerised product,
to follow transglycosylase reactions [13]. Despite this approach
being unsuccessful to date, the concept could pave the way for
new ideas on how to assay these biologically and pathophysiolog-
ically important enzymes. Eventually it may be advantageous to
move away from utilisation of highly modiﬁed substrates for
enzyme characterisation, and minimise the differences from the
physiological substrates. Furthermore, it is apparent that PBPs
function in a coordinated manner, and it may be intuitive to
includemultiple enzymes in assays. Several groups have developed
high throughput assays of the coupled transglycosylase-transpep-
tidase activities of peptidoglycan synthesis using membranes as a
source of PBPs [50,55,56], in which the transglycosylases can make
many of the interactions they would make in vivo, and are thus
being studied in a more physiologically relevant environment.
3. Known inhibitors of peptidoglycan transglycosylase enzymes
As previous eluded to, peptidoglycan transglycosylases are
under-exploited as antimicrobial drug targets, despite their key
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target for a number of existing antibiotics. Moreover, since most
pathogens have at least two transglycosylase enzymes required
for peptidoglycan biosynthesis which utilise the same mechanism,
resistance to novel compounds would require simultaneous and
multiple compensatory mutations. Additionally, the fact that the
natural product moenomycin has been used for several decades in
agriculture without reports for resistance [57], suggests promise
in the search for novel inhibitors targeting the same mechanism,
but requiring more acceptable pharmacokinetic properties for
human use. The structure, biosynthesis and chemical properties
of moenomycin have been reviewed extensively in the recent past
[9] and will not form part of this discussion except for reference
to the binding site within the transglycosylase active site. The
transglycosylases are processive enzymes utilising a donor site in
which the growing glycan chain resides anchored to the membrane
by the undecaprenyl chain of the previously appended lipid II, and
an adjacent acceptor site for the incoming lipid II monomer. As a
result, the enzyme active site is comparatively long and extended
and must accommodate at least four sugar binding sites. Similar
active site architecture is seen in lysozyme which also binds alter-
natingN-acetylglucosamine andN-acetylmuramic acid repeat units
[8]. In the following section, we summarise the latest advance-
ments in inhibitors of transglycosylation, including those based
on moenomycin and its analogues, as well as analogues of lipid II.
3.1. Moenomycin: The ‘blueprint’ transglycosylase inhibitor
The moenomycins are a family of glycolipid antibiotics natu-
rally produced as a complex of related compounds by Streptomyces
ghananensis with moenomycin A representing the major compo-
nent with antimicrobial activity [9,58]. Moenomycin consists of a
pentasaccharide of units B, C, D, E and F with a chromophore (unit
A) and a C25 lipid chain connected to the F saccharide via a phos-
phoglycerate linker (see Fig. 3). The C25 chain is required for anti-
microbial action and in essence the moenomycin structure
resembles that of the lipid IV product formed within the transgly-
cosylase active site [59].
Moenomycin has amphiphilic properties due to the hydrophilic
nature of the A to F carbohydrate units, the phosphate group of the
phosphorglycerate linker and the folded hydrophobic domain
formed by the lipid chain. Structure-activity relationships have
been carried out on the moenomycin A molecule through selective
degradation of its structure and the synthesis of di- and trisaccha-
ride analogues, resulting in an understanding of the minimal
pharmacophore [9,60,61]. The degradation of moenomycin to
chemical entities that retain the carbohydrate units C, E and F,
can be performed with retention of transglycosylase inhibition
and antibacterial activity [62,63]. Degradation to retain only the
E and F carbohydrate units, still yields transglycosylase inhibition
but with the loss of antibacterial activity [64]. The C25 lipid chain
is required to achieve full anti-bacterial activity of moenomycin,
but is also the origin of its long half-life and contributes to its poor
bioavailability and incompatibility for human consumption [9].
Decreasing the length of the lipid chain slowly reduces the inhibi-
tory ability of moenomycin [63], most likely due to loss of ability to
anchor itself into the cytoplasmic membrane. Modifying or trun-
cating the lipid chain improves pharmacokinetic properties but
the loss of activity needs to be compensated by maintaining essen-
tial polar active-site contacts or by utilisation of other hydrophobic
chemophores with acceptable properties.
3.2. The binding of moenomycin and lipid II to transglycosylase
The two natural molecules known to bind to the transglycosyl-
ase domain of PBPs are moenomycin and lipid II. The structuraldifferences between the two must be responsible for inhibition
(Fig. 1), as lipid II is the natural substrate for transglycosylation
and moenomycin is the most potent inhibitor. Understanding
how these two molecules interact and bind to the transglycosylase
domain is fundamental in pursuing structural analogues for
inhibition.
Moenomycin A binds with high afﬁnity to the transglycosylase
domain of several Class A PBPs and is the most potent inhibitor of
the transglycosylase function of PBPs with MICs in the region of
0.01–0.1 lg/mL [58]. The mode of inhibition of moenomycin is
such that it directly (and reversibly) binds to the active site of
the transglycosylase domain, preventing lipid II polymerisation. It
ﬁrst binds to the cytoplasmic membrane via its lipid chain, fol-
lowed by selective binding of the sugar moiety to the donor site
of the transglycosylase.
The transglycosylase domain contains ﬁve motifs representa-
tive of the GT51 fold-family [65] and which are conserved among
both mono- and bi-functional PBPs. Six residues in the transglyco-
sylase domain have been identiﬁed as important in the interaction
with moenomycin in Aquifex aeolicus PBP1A [24,25], and are con-
served across other species. These 6 interactions bind to the F-ring
and the phosphoglycerate portion of the drug. The transglycosylase
active site is buried in the membrane in order to access the lipid II
substrate, explaining the need for a lipid chain on moenomycin A
for its inhibitory potency. It is thought that the C25 chain of moe-
nomycin interacts with the transmembrane (TM) segment of E. coli
PBP1B [47], increasing the binding afﬁnity 5-fold of moenomycin
to the transglycosylase domain, highlighting the importance of
the TM domain for activity. The regions of moenomycin that make
essential contacts with the transglycosylase domain include the C2
on the E ring, C3 on the F ring, the phosphoglycerate moiety and
possibly the C10 region of the moenocinol lipid tail. The phos-
phoryl group and the carboxylate moiety form interactions with
conserved active site residues of the transglycosylase domain
[66]. The A unit chromophore is not essential for the interaction
but may provide higher binding afﬁnity [9].
At the time of writing, the only structural information available
for the interaction of lipid II with the transglycosylase domain is
that derived from the X-ray crystal structure of S. aureus non-func-
tional glycosyltransferase with an analogue of Lipid II [28]. The
lipid II analogue used in this study has an undecaprenyl lipid tail,
biotinylated ethylene glycol diethyl amine in place of the penta-
peptide stem and GalNAc in place of GlcNAc in the disaccharide
moiety and has a Kd of 12.9 lM. Despite the clear importance of
the undecaprenyl lipid tail of lipid II for location of the substrate
in relation to the enzyme active site, only a discrete section of
the disaccharide-pyrophosphate moiety of the lipid II is repre-
sented in the electron density at 2.3 Å resolution. The presence of
GalNAc within the lipid II analogue precludes its elongation in
the normal transglycosylation reaction, since the position 4 hydro-
xyl on the sugar ring is in the opposite orientation compared to
GlcNAc. but is proposed to bind more tightly to the active site as
the distance between that hydroxyl and main-chain carbonyl of
G130 is reduced [28].
In consideration of lipid II binding to both the donor and accep-
tor sites of transglycosylase, lipid II is thought to bind at a lower
afﬁnity for the donor site compared to that of lipid IV [14] and this
is consistent with the observation of a lag phase in catalysis, seen
with many transglycosylase enzymes in the presence of lipid II
substrate only. Many inhibitors that bind to transglycosylases
occupy the donor site, mimicking the elongating chain of polymer-
ised lipid II [7]. Lovering and co-workers have proposed that moe-
nomycin structurally mimics lipid IV [7,23], a supposition further
supported in that lipid IV and moenomycin are suggested to bind
to the same site on the transglycosylase domain [67] and that lipid
IV may bind to E. coli PBP1B with a higher afﬁnity than lipid II [14].
Fig. 3. The structure of Moenomycin A, the only known potent inhibitor for bacterial transglycosylases. The region highlighted in blue is the minimal inhibitory
pharmacophore, which is often used as a scaffold for the design of new potential inhibitors (discussed in Section 3.1).
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Finding that the moenomycin degradation products exhibit
inhibitory activity against transglycosylases prompted a study in
1999 by Soﬁa et al., to develop a combinatorial library of 1300 ana-
logues of the moenomycin disaccharide core [68]. These analogues
explored modiﬁcations at C2 of the E ring and C3 of the F ring (the
critical interaction points with the transglycosylase domain). Mod-
iﬁcations included aromatic groups attached to the E and F rings
and a lipid tail of 12 rather than 25 carbons. Three compounds
showed particular promise (Table 2: TS30663, TS30153 and
TS30888, with some being more active than the EF disaccharide.
These compounds were orders of magnitude less potent than the
parent molecule moenomycin, but had IC50 values in the range of
10–15 lM [69]. These putative inhibitors also exhibited activity
against Gram-positive strains including Enterococcus faecium
which have tolerance to moenomycin, highlighting that simple
degradation compounds show potency against clinically relevant
pathogens. The IC50 values obtained are within a similar range to
other cell wall inhibitors such as bacitracin, vancomycin and
ramoplanin. These compounds showed differing activities against
transglycosylases in different species, suggesting that they may
target different subsets of the transglycosylases [70] as is also seen
for b-lactams [71]. A new member of the moenomycin group
AC326-a was introduced by He et al. (2000) which has a cyclic
moenocinol chain, giving a diumycinol chain [72]. Branched chain
lipids show more potent antibacterial activity than linear chained
lipids. Putative inhibitors could be designed to mimic moenomycin
and could exhibit antibacterial activity to cyclic lipid chains.
Halliday et al. [6] presented a class of compounds from Alchem-
ia, based on the disaccharide scaffold of Soﬁa et al. [68] with a
focus on maintaining the important transglycosylase binding
regions. The hits had MIC values of 1–4 lg/mL, against a broad
range of Gram-positive organisms [6,68]. One example compound
from this class: ACL 19273, showed direct binding and inhibition of
the transglycosylase domain, potentially binding to either theacceptor or donor site of the enzyme [6]. Inhibitors that bind to
the transglycosylase acceptor site, which may be the case for these
small disaccharides, are binding to the contrary site to where moe-
nomycin binds. Determining whether inhibitors bind to the donor
or acceptor site of the transglycosylase is important is elucidating
their mode of action.
3.4. Lipid II analogues
In the early 1990s, efforts were focused on synthesizing trans-
glycosylase inhibitors based on monosaccharide and disaccharide
analogues of lipid II, but most were not very active [73–75]. A com-
bination of mono- and disaccharide analogues of lipid II and moe-
nomycin were synthesised by Garneau et al. based on the active
part of moenomycin and combining with structural features of
lipid II [76]. A lipid II monosaccharide analogue, Compound 5,
was designed to mimic the pyrophosphate of lipid II with a dicar-
boxylate group. Modest activity with just monosaccharide ana-
logues was exhibited, with 28% inhibition of transglycosylases at
100 lM [76]. Clearly the potency of such compounds is weak and
it may be that monosaccharide analogues do not have comparable
complexity to moenomycin, to sufﬁciently inhibit transglycosylas-
es [77].
Lipid I and lipid II substrate analogues (both mono- and disac-
charides) were synthesised by Terrak and co-workers [77–79] to
test the consequences of variations in the lipid chain length, the
pyrophosphate and the length of the peptide stem. The disaccha-
ride analogues were 2-fold greater inhibitors than their cognate
monosaccharides and as the length of the peptide stem increased
from no peptide to l-Ala-d-Glu, to l-Ala-d-Glu- l-Lys, inhibition
decreased. This was attributed to the presence of a peptide
preventing high afﬁnity binding between the GlcNAc and the trans-
glycosylase. Analogues were tested to highlight important moieties
for the future design of substrate-based inhibitors with two hits:
C16-phosphoglycerate-MurNAc-GlcNAc (Compound 21) and C16-
phosphoglycerate-MurNAc-(l-Ala-d-Glu)-GlcNAc (Compound 62).
Fig. 4. The structure of vancomycin and its derivative chlorobiphenyl vancomycin
(CBP-V), which showed antibacterial activity against vancomycin-resistant Entero-
cocci (VRE) [85] (discussed in Section 3.5).
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the transglycosylase as well as antibacterial ability.
The continuous and quantitative FRET-based assay by Huang
and co-workers (as described in Section 2.4) was used to screen
a 120,000 compound library containing a variety of bioactive and
synthetic molecules, including lipid II analogues [46]. Initially, 25
primary hits were revealed which were subjected to secondary
screening. Dose-dependent studies using HPLC and other
FRET-based assays identiﬁed 7 compounds as transglycosylase
inhibitors. The antibacterial activities and MICs were acquired,
which showed activity against S. aureus and M. smegmatis, but
not Gram-negative bacteria tested (E. coli, Pseudomonas aeruginosa
and A. baumannii). Compounds 19 and 20 were competitive inhib-
itors of transglycosylase and compounds 24 and 25 were active
small molecule inhibitors, with 24 being a previously identiﬁed
hit [80] with a salicylanilide core structure.
Huang et al. solved the crystal structure of S. aureus MGT
(SaMGT) in complex with a lipid II substrate analogue, Analogue
3, designed with an inverted 4-OH group on the GlcNAc, which
can bind more tightly to the lipid II binding pocket [28]. The
compound was used as a donor substrate only, and bound to the
SaMGT acceptor site. The purpose of this analogue was primarily
as a means to understand binding interactions with the transglyco-
sylase domain, rather than as an inhibitor per se.
The role of the pentapeptide moiety in lipid II and its mode of
interaction with the transglycosylase has been explored [81]. Lipid
II analogues with an assortment of peptide stems were synthesised
to analyse their capabilities as transglycosylase substrates. Modiﬁ-
cations include incorporating a ﬂuorescent NBD label into position
3 of the peptide or a d-lactyl group at the hydroxyl group of
MurNAc. Surface Plasmon Resonance binding studies were con-
ducted to determine the binding afﬁnity of these analogues to
transglycosylase. The three main conclusions from this work were
(a) the terminal d-Ala-d-Ala is not essential for substrate binding
and does not signiﬁcantly interact with the transglycosylase
domain, (b) the ﬂuorescent probe NBD on the e-amino group of
the 3rd position lysine does not affect binding afﬁnity to transgly-
cosylase and (c) the minimum structural requirement for the pep-
tide moiety in lipid II as a transglycosylase is d-lactyl-l-Ala. Further
research has shown that only the d-lactyl of the MurNAc is
required for the substrate binding to transglycosylase [78].
3.5. Vancomycin derivatives bind to transglycosylase
The natural product antibiotic vancomycin normally inhibits
peptidoglycan polymerisation by binding to the terminal d-Ala-
d-Ala moiety on the lipid II pentapeptide stem, inhibiting trans-
peptidation. Controversially, hydrophobic vancomycin derivatives
have been shown to inhibit peptidoglycan polymerisation through
preventing transglycosylation, most likely through binding the
transglycosylase domain of PBPs and in the absence of dipeptide
and depsi-peptide binding [34,82–84]. Common examples of van-
comycin derivatives have lipid moieties at the aglycone or on the
carbohydrates. One is produced from alkylating vancomycin on
the vancosamine sugar with chlorobiphenyl, giving chlorobiphe-
nyl-vancomycin (CBP-V) [85] (Fig. 4). CBP-V showed antibacterial
activity against vancomycin-resistant strains, e.g. vancomycin-
resistant Enterococci (VRE), where the di-peptide moiety in lipid
II is substituted for d-Ala-d-lactate.
When the vancomycin N-terminal methyl leucine required for
binding d-Ala-d-Ala, was removed from chlorobiphenyl vancomy-
cin (yielding chlorobiphenyl desleucyl-vancomycin), the derivative
retained antibacterial activity for both sensitive and resistant bac-
teria, despite no longer being able to bind its di-peptide ligand
[85]. In contrast, when the N-terminal methyl-leucine was
removed from full-length vancomycin, it could no longer bind tothe d-Ala- d-Ala of lipid II and so was no longer active. The mech-
anism of action of chlorobiphenyl desleucyl-vancomycin on vanco-
mycin sensitive strains is through either binding the d-Ala-d-Ala
of lipid II, or by preventing transglycosylation. Chlorobiphenyl
desleucyl vancomycin is missing an important portion of the di-
peptide binding pocket [85]. Activity of the vancomycin derivatives
decreases when the peptide-binding pockets are damaged [34],
suggesting that inhibition is through a mechanism not involving
di-peptide binding [84].4. Prospects for new transglycosylase inhibitors
Developing new drugs with antibacterial properties through
inhibition of peptidoglycan transglycosylation is of current interest
to both academia and the pharmaceutical industry. Currently, most
compounds discovered, summarised in Table 2 have greater
potency against Gram-positive bacteria than Gram-negative
presumably due to accessibility, as is the case with many other tar-
geted compounds. Progress on the development of transglycosyl-
ase inhibitors has been slow historically due to complexity of the
active site of the enzymes, lack of suitable assays for high through-
put screening, provision of suitable substrates for such assays and
the difﬁculties surrounding the reconstitution of activity of these
membrane proteins. The availability of lipid II substrate from
chemi-enzymatic and total chemical synthesis domains allows
transglycosylases from various species to be studied along with a
growing literature detailing molecular architecture interactions
within the active site. Further understanding of substrate speciﬁc-
ity will aid the design of future substrate analogues, common fea-
tures of which are becoming apparent.
The development of glycolipids and glycopeptides as putative
transglycosylase inhibitors has shown that there are new prospects
for the combinatorial biosynthesis of phosphoglycolipid antibiotics
[86] and there are new generation glycopeptides currently in clin-
ical development that inhibit the transglycosylation process [87].
N.F. Galley et al. / Bioorganic Chemistry 55 (2014) 16–26 25In addition, research is on-going to determine the exact inhibitory
mechanism of moenomycin on transglycosylases, with a drive
towards ﬁnding novel inhibitory compounds with distinct struc-
tural features. Total synthesis of moenomycin A has been achieved
[88] and the biosynthetic pathway variants can be theoretically
generated which could help in the quest to design new compounds
with better pharmacokinetics [89].
We now have the ability to synthesise structurally diverse sub-
strates and to combine synthetic and biological compounds by
either enzymatic modiﬁcation of synthetic analogues or by chem-
ical modiﬁcation of biosynthetic intermediates. These capabilities
enable better comprehension of the role of lipid II in binding to
the transglycosylase domain and help to optimise structures for
the transglycosylase donor and acceptor sites. These sites have dif-
ferent requirements for lipid chain length, which is important for
the processivity of the transglycosylase, with the donor site requir-
ing a C20 lipid chain and the acceptor site tolerating shorter lipids,
so there is a compromise between lipid chain length and antibiotic
activity [90]. Walker and co-workers have predicted that lipid II
with four successive cis isoprene units in a 35-carbon chain is
the best transglycosylase substrate [21]. Investigating the optimal
substrate for transglycosylases such as lipid IV or longer as poten-
tial substrate inhibitors may be a worthwhile focus and could be
fruitful in generating moenomycin mimics, without the poor phar-
macokinetics [14]. Despite the evolution of structurally diverse
substrates, there is still more room to understand transglycosyl-
ase-substrate mimics.
The structures of transglycosylase domains resemble more clo-
sely the structures of glycosidases such as lysozyme, rather than
other glycosyl-transferases. Therefore, glycosidases may be better
representatives for inhibitor design and lessons may be learned
from several decades of experience with the great glycosyl-
transferase families [65]. Although there are now in the region of
ten structures of transglycosylase enzymes in the protein data-
bank, only a small subset are below 2.5 Å resolution and thus reli-
able for structure based drug design efforts. This does include
however the S. aureus monofunctional enzyme in apo (2.5 Å) and
lipid II analogue (2.3 Å) forms [28] and the 2.2 Å E. coli PBPIb
structure in complex with moenomycin [27]. Curiously, the latter
structure is monomeric whereas the enzyme in solution has been
shown to dimerise at a Kd well below that achieved in both crys-
tallisation and presumable in-crystallo [42]. The recent crystal
structures of transglycosylase domains in complex with moeno-
mycin have highlighted essential interactions but their signiﬁcance
in structure based drug design efforts must be viewed in the
context of the overall processive transglycosylase mechanism.
In the recent past, a number of robust high throughput assays
for screening have emerged that provide new prospects for inhib-
itor discovery. As with all such efforts, the quality and suitability of
such libraries must be carefully considered to maximise the poten-
tial outputs. The development of a ﬂuorescence polarisation based
assay utilising a weaker binding derivative of moenomycin in a dis-
placement assay scenario is particularly encouraging in this
respect [48]. Cell based screening assays are also worthy of discus-
sion in this context since they preselect those compounds with the
required properties to gain entry to the target cell and are selected
on bacteriostatic or bactericidal effects. A set of compounds with a
non-carbohydrate, salicylanilide core were identiﬁed by Cheng
et al. and showedmodest inhibitory action against transglycosylas-
es, providing an alternative starting point for medicinal chemical
approaches [80].
Further knowledge of the catalytic mechanism and in vivo reg-
ulation of transglycosylation activity may provide further insight
into the chemistry of potential novel lead compounds required
for effective chemotherapeutic intervention. Given the renaissance
of interest in antimicrobials, the growing concern by public andpolicy makers regarding antibiotic resistance, the development of
new approaches and collaborative efforts between academia and
pharma, progress in inhibitor design against transglycosylase
may be on the horizon.
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